SCHEMBL2655191

SCHEMBL2655191

Cc1csc(CC(=O)O)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 4/20 0.40
MCL1 Q07820 2/20 0.39
PTGS2 P35354 2/20 0.38
CMA1 P23946 3/20 0.36
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
KMT2A Q03164 1/20 0.35
AKR1B1 P15121 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRB2 P47870 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CLIC1 O00299 1/20 0.34
CXCL8 P10145 1/20 0.34
CLCN2 P51788 1/20 0.34
ADAMTS5 Q9UNA0 1/20 0.34
ADRA2A P08913 1/20 0.33
ADRA2B P18089 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27374878 0.77 HSD17B10 (0.42) PTGDR2PTGS2KDM4EMEN1ALDH1A1
SCHEMBL6977262 0.77 AGBL2 (0.39) PTGDR2PTGS2KDM4EMEN1ALDH1A1
Cyclopropane SCHEMBL11665858 0.76 ADRA1D (0.36) PTGDR2PTGS2KDM4EMEN1ALDH1A1
SCHEMBL2986172 0.75
SCHEMBL6561734 0.74 ALDH1A1 (0.35) PTGDR2KEAP1NFE2L2MEN1ALDH1A1
SCHEMBL28007558 0.74 THRB (0.34) PTGDR2KEAP1NFE2L2KDM4EMEN1
SCHEMBL21737582 0.73
SCHEMBL11348514 0.72 PTGS2 (0.56) PTGS2KMT2AAKR1B1CLIC1CXCL8
SCHEMBL11348988 0.71 PTGS2 (0.58) PTGS2MEN1ALDH1A1KMT2ACLIC1
SCHEMBL15532260 0.71 DAO (0.33) MCL1CMA1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088584-A1 PROCESS FOR PREPARING 3, 4-DISUBSTITUTED PHENYLACETIC ACIDS AND NOVEL INTERMEDIATES DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) 2009-04-02 US disclosed
EP-1986995-A1 PROCESS FOR PREPARING 3, 4-DISUBSTITUTED PHENYLACETIC ACIDS AND NOVEL INTERMEDIATES DSM Fine Chemicals Austria Nfg GmbH & Co KG (AT) 2008-11-05 EP disclosed
US-20070284258-A1 Method For Silver Plating DAIWA FINE CHEMICALS CO., LTD. (JP) 2007-12-13 US disclosed
US-20070254895-A1 Crystalline solvate of glucokinase activator CHOI DUK SOON 2007-11-01 US disclosed
WO-2007115968-A2 PROCESS FOR THE PREPARATION OF A GLUCOKINASE ACTIVATOR F. HOFFMANN-LA ROCHE AG (CH) 2007-10-18 WO disclosed
WO-2007115967-A1 CRYSTALLINE ISOPROPANOL SOLVATE OF GLUCOKINASE ACTIVATOR F. HOFFMANN-LA ROCHE AG (CH) 2007-10-18 WO disclosed
US-20070244129-A1 Process for the preparation of an isopropanol solvate of a glucokinase activator DANIEWSKI ANDRZEJ ROBERT 2007-10-18 US disclosed
WO-2007096034-A1 PROCESS FOR PREPARING 3, 4-DISUBSTITUTED PHENYLACETIC ACIDS AND NOVEL INTERMEDIATES DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) 2007-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088584-A1 PROCESS FOR PREPARING 3, 4-DISUBSTITUTED PHENYLACETIC ACIDS AND NOVEL INTERMEDIATES PAH, CTRC, DDC PTGDR2 1711/4885MCL1 3238/4885PTGS2 4066/4885
US-20070244129-A1 Process for the preparation of an isopropanol solvate of a glucokinase activator GCKR, GCK, GK PTGDR2 1354/4885MCL1 4404/4885PTGS2 915/4885
US-20070254895-A1 Crystalline solvate of glucokinase activator GCKR, GCK, PDXK PTGDR2 2173/4885MCL1 4706/4885PTGS2 1331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.